-
US automakers report mixed sales as car market awaits war impact
-
Astronauts begin NASA lunar mission after climactic blast-off
-
Astronauts blast off for historic US lunar journey
-
Embattled Woods won't captain 2027 Ryder Cup team: PGA of America
-
Judge allows Woods to travel overseas for treatment
-
Chelsea's Bompastor furious as Arsenal reach women's Champions League semis
-
US lifts sanctions on Venezuelan interim leader Delcy Rodriguez
-
Arsenal resist Chelsea rally to reach women's Champions League semis
-
Defending champ Pegula wins WTA Charleston opener
-
New frog species carrying eggs on back discovered in Peru
-
Benfica winger Prestianni denies 'ugly' racism claims
-
Tuchel casts doubt on Foden's World Cup chances
-
Slot hoping Salah can still burnish Liverpool legacy
-
Astronauts strapped in for historic US lunar launch
-
Top World Bank official 'extremely concerned' by fallout of Iran war
-
'Wake-up call': Megan Thee Stallion falls ill during Broadway show
-
Canada's defense enters new phase, Arctic in focus: top military officer
-
France charges man over failed attack on US bank
-
Bayern reach women's Champions League semis after late show sinks United
-
SpaceX files to go public, paving way for record stock offering
-
Delhi make winning start to IPL as Rizvi downs LSG
-
Final ticket sales phase begins for FIFA World Cup
-
Supreme Court skeptical of Trump bid to end birthright citizenship
-
Tractors roll through Vienna as farmers protest
-
PGA Tour, Masters chairman support Tiger recovery pause
-
World Cup winner Goetze extends contract at Frankfurt
-
SpaceX files securities documents to go public: source
-
Armenia cannot be in both EU and Russian customs bloc, Putin says
-
Supreme Court hears landmark citizenship case -- with Trump in audience
-
Chelsea announce record pre-tax loss of £262.4 million
-
Stocks rally, oil drops on Mideast war optimism
-
Starmer says UK to host multi-nation meeting on Hormuz shipping
-
Greece train crash trial resumes after courtroom chaos
-
Trump says Iran asks for ceasefire as Tehran hit by fresh strikes
-
Swiss government eyes dropping purchase of US Patriot air defence system
-
Germany halts rescue efforts for stranded whale
-
IndiGo lands IATA chief Willie Walsh as new CEO
-
Late charging Ganna denies Van Aert at Across Flanders
-
'Embarrassed' Spain probes anti-Muslim chants at Egypt friendly
-
Family of man killed in 2020 arrest to sue French state
-
The 'million dollar' Senna helmet bought at Japan GP
-
Could NATO be collateral damage from Trump's Iran war?
-
Supreme Court hearing landmark citizenship case -- with Trump in audience
-
Three go on trial in Germany over plot to overthrow government
-
Anderson backs England for Australia revenge despite Ashes woes
-
Italy's sport minister asks football chief to step down after World Cup disaster
-
Cambodia extradites accused cyberscam boss to China
-
Supreme Court to hear landmark citizenship case -- with Trump in audience
-
UK police arrest three more over Jewish ambulance attack
-
Wallaby Skelton has 'season cut short' by Achilles injury
Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
W.Lapointe--BTB